Rapid generation of replication-deficient monovalent and multivalent vaccines for bluetongue virus: protection against virulent virus challenge in cattle and sheep

Cristina CP Celma¹, Mark Boyce¹, Piet A van Rijn², Michael Eschbaumer³, Kerstin Wernike³, Bernd Hoffmann³, Martin Beer³, Andy Haegeman⁴, Kris De Clercq⁴ and Polly Roy¹#

¹ Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; ² Central Veterinary Institute of Wageningen University, Department of Virology, 8200 AB Lelystad, The Netherlands; ³ Institut für Virusdiagnostik, Friedrich-Loeffler-Institut, Südufer 10, 17493 Greifswald-Insel Riems, Germany; ⁴ CODA-CERVA, Department of Virology, Unit of Vesicular and Exotic Diseases, Ukkel, Belgium.

Running title: Replication-deficient BTV vaccines

Keywords: BTV, reverse genetics, disable infectious single cycle virus

Word count:  Abstract: 187

Text: 3435

# Corresponding author mailing address: Professor Polly Roy, London School of Hygiene and Tropical Medicine, Keppel St., WC1E 7HT, United Kingdom. Tel.: +44(0)20-79272324; Fax: +44(0)20-79272839; e-mail: polly.roy@lshtm.ac.uk
ABSTRACT

Since 1998, nine of the 26 serotypes of bluetongue virus (BTV) have spread throughout Europe and serotype 8 has suddenly emerged in northern Europe causing considerable economic losses, both direct (mortality and morbidity) but also indirect due to restriction in animal movements. Therefore many new types of vaccines, particularly subunit vaccines, with improved safety and efficacy for a broad range of BTV serotypes are currently being developed by different laboratories. Here we exploited a reverse genetics-based replication-deficient BTV-1 serotype (disabled infectious single cycle, DISC) to generate a series of DISC vaccine strains. Cattle and sheep were vaccinated with these viruses either singly or in cocktail as multivalent vaccine candidate. All vaccinated animals were seroconverted and developed a neutralizing antibody response against their respective serotype. After challenge with the virulent strains at 21 days post vaccination vaccinated animals showed neither any clinical reaction nor viremia. Further, there was no interference in protection with a multivalent preparation of six distinct DISC viruses. These data indicate that a very rapid response vaccine could be developed based on which serotypes are circulating in the population at the time of an outbreak.
INTRODUCTION

Vaccination is one of the most effective approaches for controlling infectious viral diseases to date. Extensive knowledge of the basic biology of viruses at the molecular level coupled with recent technology developments have resulted in a number of newly designed vaccines for both human and animal viral diseases. However, the generation of effective vaccines for viruses with multiple distinct serotypes remains laborious and highly challenging. The insect-borne Bluetongue virus (BTV) consists of 26 serologically distinct viral serotypes (1). BTV is the causative agent of bluetongue (BT) disease of ruminants (sheep, goats, and cattle) with sheep being the most susceptible host with the highest mortality rate. BTV is endemic in both tropical and sub-tropical countries of the world, and it was considered exotic in Europe prior to 1998. However, several outbreaks of a number of BTV serotypes in Europe, which caused significant losses in European livestock and agriculture, have since been reported.

BTV belongs to the Orbivirus genus in the Reoviridae family, and like other members of the family, BTV is a non-enveloped icosahedral particle. BTV possesses a complex double-capsid structure consisting of seven structural proteins (VP1 to VP7) and a genome of 10 double-stranded RNA (dsRNA) segments. The outer capsid is made up of two major proteins, a larger ~110kDa protein VP2 and a 60kDa VP5 protein. VP2 is a highly variable, serotype-determining protein, and it binds to the cellular receptor. VP5 is less variable and is a membrane penetration protein. These two proteins loosely interact with each other and both are directly attached to the surface layer of the inner capsid (termed the core), which consists of the remaining five structural proteins and the viral genome. The core surface layer is made up of multiple copies of a single major protein, VP7. VP3 forms an inner scaffolding layer for the VP7 layer, which in turn, surrounds the three minor proteins VP1 (polymerase), VP4
(capping enzyme) and VP6 (helicase) in addition to the genomic dsRNAs. In addition, four non-structural proteins (NS1 to NS4) are synthesised in virus-infected cells. Both core proteins and NS proteins, unlike the outer capsid proteins, are highly conserved among BTV serotypes (2).

Although vaccination has been an effective approach to control BTV spread, currently available vaccines are associated with undesirable side effects. There are two types of BTV vaccines commercially available, conventional live-attenuated and chemically inactivated. Although both types of vaccine can protect against BTV infection, problems such as incomplete protection, association with teratogenic effects, and incomplete attenuation have been reported (3, 4). Consequently, there are many current efforts to develop new types of vaccines with improved safety and efficacy for a broad range of BTV serotypes (5-11). Most of these efforts concentrate on the development of subunit vaccines.

Recently, we exploited a BTV reverse genetics technology to develop replication-deficient BTV serotypes based on the introduction of a lethal mutation in one of the replication essential genes, the viral helicase protein VP6 (12). We have demonstrated that the VP6 deletion viruses (disabled infectious single cycle, DISC) could only replicate in a VP6-complementing cell line but were excellent in inducing protective neutralizing antibody responses in vaccinated animals. As BTV genome segments reassort readily among different serotypes, it was possible to utilise the VP6 DISC virus strains to generate alternate serotypes by exchanging the two RNA segments that encode the two outer capsid proteins of a different serotype.
In this report, we have extended this approach to the generation of a series of monovalent disabled BTV serotypes, including the recent European serotypes that have caused serious disease in animals. The immunogenicity of each disabled virus strains was then assessed in the animal hosts. Furthermore, due to the precedent set by three polyvalent, attenuated live virus vaccines (each containing five serotypes) currently in use in South Africa to control bluetongue disease, we tested the DISC viruses in sheep as a multivalent vaccine candidate. The ratio of specific serotypes in each preparation was calculated to prevent interference in the immunity between strains due to cross-reactivity. Our data show clearly that there was no interference in protection with a multivalent preparation of six distinct serotypes of DISC viruses and that full protection was conferred against all six serotypes. The ease of effective DISC vaccine development will facilitate the inclusion of new serotypes to existing vaccination programmes. In this manner, a very rapid response vaccine could be developed based on which serotypes are circulating in the population at the time of an outbreak.

MATERIALS AND METHODS

Cells and viruses. BSR cells (BHK-21 subclone) were maintained in Dulbecco modified Eagle medium (DMEM, Sigma Aldrich) supplemented with 5% (v/v) fetal bovine serum (FBS, Invitrogen). The stable BSR9 (BSR-VP6) cell line was grown in DMEM-5%FBS supplemented with 7.5g/ml of puromycin (Sigma Aldrich). BTV serotype stocks were generated by infecting BSR cells and harvested at 100% cytopathic effect. The challenge strains (BTV-2/SAD2001/01, BTV-4/MOR2009/0, BTV-8/DE2008) had been isolated and grown in embryonated chicken eggs and/or cell culture (passage level E1/BHK2/KC1, KC1 and VERO2, respectively). The inoculated doses were confirmed by titration on mammalian Vero and insect KC (derived from Culicoides) cells.
Rescue of reassortant disabled viruses in complementing cell line

Segments S2 (VP2) and S6 (VP5) from BTV-2, BTV-4, BTV-8, BTV-10, BTV-13, BTV-21, and BTV-24 were obtained using a sequence independent system as has been described (13, 14). Briefly, dsRNA from purified core particles were ligated to a self-annealing primer, before RT-PCR using a specific primer. cDNA amplified from segments S2 and S6 of the above mentioned serotypes were cloned into pUC19 and fully sequenced (Source Bioscience) before insertion of the T7 promoter at the 5’ end and insertion of a unique restriction enzyme site that generates the correct end of the segment at the 3’ end. Modified segments S9 with either a deletion in the coding sequence of VP6 or a deletion and insertion of the EGFP gene were described previously (12, 15).

For synthesis of uncapped T7 transcripts for segments S2 and S6, RiboMAX Large-Scale RNA Production System T7 (Promega) or TranscriptAid T7 High Yield Transcription Kit (Thermo Scientific) kits were used according to manufacturer’s instructions. Reassortant viruses were rescued from confluent monolayers of complementing cells (BSR9) transfected with six plasmids that drive the expression of BTV proteins VP1, VP3, VP4, VP6, NS1 and NS2 as described previously (16) prior to transfection with seven T7-derived ssRNAs from BTV-1, one of the modified S9 (S9Δ or S9Δ-EGFP) ssRNAs, and a combination of S2 and S6 ssRNA from a particular serotype.

Reassortant defective viruses were rescued and grown in the complementing cell line BSR9 as described previously (15). Titration of all defective viruses was performed in BSR9 cell line, and the virus titer was determined by plaque assay or tissue culture infective dose 50 (TCID50).
Vaccination and virus challenge

For the monovalent vaccine test, eighteen BTV-naïve heifers between 9 and 18 months of age were used for the animal experiment. Three vaccine groups of three heifers each were inoculated with one of the reassortant disabled viruses (BTV-2D, -4D or -8D) using two doses 21 days apart. Nine received a lysate from BSR9 cells and were kept as controls. Vaccine identity and dose were confirmed with the TaqVet European BTV Typing kit (LSI, France). The type-specific quantification cycle (Cq) values for the reassortant viruses were 16.5, 15.2 and 15.1, respectively. Injection sites were examined daily for one week after each immunisation to detect local reactions.

Clinical surveillance based on the CVI score (17) and measurements of rectal temperature were conducted daily from four days before the first vaccination until the end of the challenge experiment (day 63). A rectal temperature of an individual animal that was more than one degree (°C) higher than the average rectal temperature on the three days before challenge was considered fever. An increase of more than 1 degree over the baseline temperature was awarded 1 point, more than 1.5 degrees 2 points, and more than 2 degrees 3 points on the CVI score sheet.

Serum samples were taken at 4, 5, 7, 10, 12, 14 and 21 days after both the first and second vaccination. On day 42 after the first vaccination, the vaccine groups and three controls each were challenged with a virulent BTV strain of the same serotype as the vaccine. Each animal was subcutaneously injected with 4 x 10⁵ TCID₅₀ of virus.

Whole-blood samples (with EDTA anticoagulant) were taken on days 0, 3 to 7, 9, 12, 14, 17, 19 and 21 days after challenge (dpc), and serum samples were collected at 0 and 21 dpc.
For cocktail vaccine test sheep were used and experiments were performed under the guidelines of the European Community (86/609) and were approved by the Committee on the Ethics of Animal Experiments of the Central Veterinary Institute (Permit Number: 2012-029). Twenty-seven female Blessumer sheep of 6–24 months old and free of BTV and BTV-antibodies were commercially sourced from the same flock of a Dutch farm. The sheep were randomly allocated to three groups of six animals and one group of nine animals. On day 0 (0 dpv) and 21 dpv, groups of six sheep were subcutaneously (s.c.) vaccinated in the neck with 2 ml of multivalent DISC vaccine. The group of nine sheep served as control and were similarly injected with an equivalent of lysate from BSR9 cells. On 35 dpv, control sheep were randomly divided over the three groups of six vaccinated sheep. On day 42, these newly formed groups of six vaccinated and three control sheep were challenged subcutaneously with 4 x 1 ml of $10^5$ TCID$_{50}$/ml of either virulent BTV-2 or BTV-4 or BTV-8. Virus was injected subcutaneously to sheep between the shoulder blades left and right from the spinal cord. Three weeks after challenge at 63dpv and 21dpc the trial was finalized.

Body temperature was recorded daily in periods of injections. Fever was defined as the average temperature plus two times the standard deviation. Clinical signs were daily recorded according to the clinical score Clinical surveillance based on the CVI score table for BTV8 animal trials (17). Samples of EDTA blood and serum were frequently collected until the end of the experiment.

**Serum neutralization assay**

For detection of neutralizing antibody response in vaccinated animals, standard serum neutralization assay of BTV was used as described previously (12). Briefly, serum samples were serially diluted 1:2 and added to confluent monolayers of BSR cells in 96 well plates.
About 100 plaque formation units of each BTV serotype were added per well and incubated for 3 days. All dilutions were performed in triplicate in each experiment. The neutralizing titers were defined as the highest dilution of sera allowing complete neutralization of the virus.

**BT competition ELISA and Early Detection ELISA**

Serum samples were analysed with the ID Screen® Bluetongue Competition assay and the ID Screen® Bluetongue Early Detection (ID VET, Montpellier, France) according to the manufacturer’s instructions. In addition to the kit controls, a twofold dilution series of an anti-BTV antibody positive reference serum (CIRAD, Montpellier, France) was included for the competition assay as working standard in each assay to monitor the performance of the ELISA in time. Results were expressed as percentage of negativity (%Negativity) compared to the negative kit control and transferred to a positive (% S/P >30), uncertain (% S/P ≤30 but >25) or negative (% S/P ≤25) result according to cut-off values previously determined (18).

**RNA extraction and RT-qPCR**

RNA extraction from the EDTA-blood samples was performed according to Vandenbussche et al. (19). The triplex RT-qPCR assay included primers and probes for a Pan-BTV/S5-specific reaction and for an internal control (IC) and external control (EC) as described before (19) and was performed on a LightCycler-480 (Roche Diagnostics, Mannheim, Germany).

For this assay, crossing point values (Cp values) <40.0 were classified as positive, Cp values = 40.0 and <45.0 were classified as uncertain and Cp values >45.0 were considered as negative (Neg). The acceptance criteria for the IC were set at a Cp value of 28.9 and for the EC at a Cp value of 33.6 for blood samples.
RESULTS

Rescue of seven disabled BTV serotypes by exchanging the two RNA segments responsible for serotype determination

As the first step in the development of a new generation BTV vaccine, a previously described sequence-independent strategy (13, 14) was used to clone segments S2 and S6 (encoding VP2 and VP5, respectively) from six different BTV serotypes (-2, -4, -10, -13, -21 and -24).

Subsequently, the resulting clones of all the segments were fully sequenced. In order to generate T7 transcripts with the exact ends for both segments S2 and S6 of each of the six serotypes, the T7 promoter and a unique restriction site at the end of each segment were introduced as described previously (13).

Reassortant disabled viruses were rescued in BSR-VP6 complementing cells (BSR9) that were transfected with ten RNA transcripts; seven of which were from BTV-1 (S1, S3-S5, S7, S8 and S10), a mutated segment S9 of BTV-10 that was incapable of the correct expression of the essential viral protein VP6 (15), and the S2 and S6 segments from one of the serotypes. The ability of the VP6 expressing cell line (15) to constitutively express VP6 under selective pressure was used to overcome the lack of a functional VP6 in the rescued system. Each rescued virus (namely BTV-2D, -4D, -10D, -13D, -21D and -24D) was propagated further, genomic dsRNAs were isolated and their gel electrophoresis profiles were compared to that of the wild-type BTV-1 (Fig. 1A). Samples of genomic dsRNAs of BTV-1D and BTV-8D, generated previously (12), were also included as positive controls.

To confirm that these reassortant disabled viruses were incapable of growth in normal cells, to exclude any recombination or reversion, and to determine the efficiency of their growth in...
complementary cells, the growth kinetics of each virus was evaluated by infecting both cell lines at low MOI and measuring the virus titers at 18, 24 and 48 hours post-infection. The results obtained demonstrated that these viruses were not able to grow in normal BSR cells since no infectious virus particles could be detected 18 hours post-infection (Fig. 1B, upper panel). However, each virus was capable of replication in the complementary cells with titers ranging from $1.3 \times 10^4$ (BTV-10D) to $1.7 \times 10^6$ (BTV-2D) at 48 hours post-infection (Fig. 1B, lower panel).

**Monoseroype vaccine strains protect cattle from virulent virus challenge**

In our previous report, we demonstrated that two BTV-1D and BTV-8D viruses were able to elicit neutralizing antibody responses in sheep that conferred full protection against homologous virulent virus challenges. Since BTV-8 had not only caused severe BT disease in sheep but also in cattle during the BTV-8 outbreaks in Europe (20-22), it was important to assess the protective efficacy of the BTV-8D vaccine strain in cattle. For comparison, two new vaccine strains, BTV-2D and -4D were also assessed in cattle in parallel as monovalent vaccines. BTV-naïve heifers were segregated into 3 groups, and each group was vaccinated twice at 21 days apart with one of the three vaccine strains as described in Materials and Methods. As a control, 3 groups of 3 heifers each were inoculated with a complementing BSR9 cell lysate. No major side effects were observed after each vaccination indicating vaccines were well tolerated. When the humoral immune response to each vaccine was assessed with the competitive ELISA (cELISA), it was clear that the response was fairly weak after the first vaccination (V1). However, all vaccinated heifers had seroconverted 5 days post second vaccination (V2) when assessed by the specific cELISA test (Fig. 2A). The result of the Early Detection-ELISA demonstrated a more pronounced IgM response.
especially in the BTV-4D and -8D groups (Fig. 2B) where 5 out of 6 animals seroconverted at 7 days post vaccination (dpv) with the 6th animal seroconverting at 10 dpv. Although this seroconversion was transient (all animals were again negative at 21 dpv), the animals in these 2 groups responded quicker to the second vaccination with 5 out of the 6 animals becoming positive at 5 days post revaccination (day 26). The IgM response in the BTV-2D was more heterogeneous and weak. None of the control group animals presented specific antibodies against BTV and only became BTV positive after virulent virus challenges.

Serum neutralization tests (SNT) were undertaken on all serum samples on the day of challenge using BTV-2, BTV-4 and BTV-8 to determine if the heifer had elicited a response prior to virulent virus challenge. Sera from all vaccinated heifer had neutralising antibody (NA) specific to the serotype of the vaccine virus and the NA titers ranged from 16 to 32. In comparison, the control heifer vaccinated BSR9 lysate did not have any detectable NA.

Viremia in both vaccinated and control groups were determined from day 3 onwards after challenge. The protection conferred by the vaccines was assessed by BTV-specific quantitative real-time RT-PCR to detect virus replication. No BTV replication was detectable in any of the vaccinated heifers (Fig. 3). In contrast, all animals in control groups became BTV positive in the real-time RT-PCR after the virulent virus challenges. These results indicated that the disabled strains were not able to replicate in vaccinated animals as no genomic RNA were detectable during the vaccination period. This data supports the safety of these vaccine candidate strains. More importantly, these data also indicated that these defective viruses were able to elicit strong immune responses that protected all vaccinated animals from homologous virulent virus challenges. Overall, these results complement our
results presented in a previous report using a different animal host where all vaccinated sheep were protected by a monovalent vaccine for BTV serotypes -1 and -8 (12).

A multivalent cocktail vaccine can protect sheep against multiple serotypes

Simultaneous circulation of more than one serotype of BTV emphasises the necessity of a vaccine that protects against several serotypes. Working towards the development of a multiserotype vaccine, we decided to test a cocktail mixture of six disabled viruses including serotypes BTV-1D, -2D, -4D, -8D, 13D and -21D. Some of the serotypes included in the vaccine represent important strains circulating in Europe in the last few years.

Three groups of six sheep were inoculated with the cocktail vaccine in a prime and boost protocol. One group of nine sheep received an equivalent of cell lysate and served as control group. Blood samples were collected at regular intervals over the experimental period to determine serological response to the vaccination and for detection of the virus replication. In parallel, body temperature, as a sign of disease, of all groups were recorded routinely.

Presence of BTV antibody in vaccinated sheep was monitored based on VP7, the group specific antigen using two different ELISA test; Early Detection and cELISA (Fig.4A & B). All vaccinated sheep showed seroconversion at 8 dpv. This initial response was transient in 4 of the 18 animals after the first vaccination and had titer below the threshold (negative) prior to the second vaccination (day 21), this trend was evident in both ELISA test used. However, all animals were seroconverted at 4 dprv (day 25) and remained positive until the end of the trial. The control sheep vaccinated with the BSR9 lysate did not elicit a response to VP7 until 7 days post challenge with virulent BTV.
The serum from the control and vaccinated animals collected on the day of the challenge was also tested by SNT using BTV-1, -2, -4, -8, -13 and -21 to determine if vaccinated animals elicited serotype-specific NA. All animals vaccinated with the cocktail vaccine had neutralising antibodies against all the homologous serotypes included in the cocktail (Fig.5). The NA titer ranged between 16 and 128 for all serotypes tested and there was no apparent interference in the ability of the animal to respond to each of the vaccine strains present in the cocktail (Fig.5). This result indicates that the cocktail vaccine would be able to protect animals against all different serotypes included in the cocktail vaccine.

Moreover, the recorded temperature in all groups showed no major differences between control and vaccinated animals before challenge (Fig.6A). The only side effect from vaccination included one animal in a control group that had a high temperature after second inoculation with cell lysate (control group) that lasted for a very short period of time. After challenge, vaccinated sheep did not develop fever, whereas control sheep had fever for several days; 2-3 days, 4-12 days, and 4-6 days for BTV-2, -4 and -8, respectively, with a peak at 7 days post-challenge for all control sheep (day 49). After challenge, three vaccinated sheep showed a slightly increased rate of breathing, mild depression and less appetite after challenge with virulent BTV-2 for more than one day. All other vaccinated sheep showed no clinical signs or only very mild signs, like less appetite for one day. Unvaccinated sheep showed severe clinical signs after challenge for several days based on CVI clinical score (17). Challenge with BTV-2 resulted in increased breathing, mild nasal discharges, less appetite, and mild depression. These clinical signs lasted for a longer period than for sheep challenged with BTV-4 and -8. Sheep challenged with BTV-4 or -8 showed very severe clinical signs, including no appetite, depression, increased breathing, painful feet, loss of body weight, and
high fever. One of three control animals in both groups died or was euthanized for ethical reasons due to clinical signs associated with Bluetongue disease.

The safety and protection conferred by the cocktail vaccine was analyzed by real-time RT-PCR in blood samples taken routinely (Fig.6B). Following both vaccinations, traces of the vaccine RNA were detected in all animals with very low copy numbers (67% was below 1500 copies per reaction with a maximum of 7300). This detection was transient with 50% of the animals becoming negative at 4 dpv. Two animals remained borderline positive until 11 dpv. The detection period upon revaccination was significantly shorter as the animals were only borderline positive at 2 dprv with the exception of 1 animal which was positive until 4 dprv. None of the sample from vaccinated animals that were challenged with BTV-2, BTV-4 or BTV-8, exhibited any virus replication. In comparison, all control animals showed virus replication as expected (Fig.6B).
DISCUSSION

Early attempts for vaccination against BTV used serum from infected sheep that had survived from the disease (23). This mild strain of virus was serially propagated in sheep. This vaccination was used for many years in South Africa despite the fact that the vaccine was found not to be safe, and it did not provide adequate immunity. Subsequently, live-attenuated virus vaccines of multiple BTV serotypes were developed by serial passage in embryonated chicken eggs. Because of the number of serotypes of BTV circulating, multivalent vaccination has generally been used in endemic areas (24) reviewed in (25). Despite the success of attenuated vaccines in endemic areas, the use of such vaccines has some drawbacks. Teratologic effects as a result of vaccination with attenuated BTV are well documented (26). Furthermore, viremia following vaccination in both laboratory experiments and in the field has been sufficient for the vaccine strain to be transmitted (27).

In this report we extended our previous work on the development of a new generation of vaccines against BTV based on the generation of disabled viruses that cannot replicate in animals or normal cells but only in a particular complementary cell line. We combined the genome segment reassortment capability of the virus to replace the outer capsid proteins (encoded by S2 and S6) of a defective BTV-1 (BTV-1D) strain using the reverse genetics system. This had allowed us to rapidly generate new vaccine strains of various serotypes that still retained the deficiency in virus replication in normal cells and can only be propagated on specific complementing cells. Moreover, after 8 serial passages, neither any reversion to virulence nor any cytopathic effect in normal cells was detectable indicating that these viruses are stable and potentially excellent vaccine candidates.

Initially, we tested three of these vaccine strains (BTV-2D, BTV-4D and BTV-8D) in cattle since infected cattle generally have prolonged viremia mostly without any BT disease.
symptoms (except the recent scenario of BTV-8 in European cattle), and therefore cattle are considered the major reservoir for the virus replication. When groups of cattle were vaccinated with one of the vaccine strains (BTV-2D, BTV-4D or BTV-8D) in a two-dose protocol and challenged with a homologous virulent strain, all developed positive immune response that inhibited challenge virus replication, as no BTV genome could be detected by highly sensitive real-time PCR and there was no clinical sign of BTV disease in any of the vaccinated animals. The data demonstrated that these defective virus strains are very effective in inducing protective immunity in vaccinated cattle similar to the results of a previous sheep study (12). Further, a two-dose protocol of three weeks apart seems to be adequate to confer complete protection. These data are comparable to those achieved with inactivated vaccines in cattle (28-30).

In some endemic areas such as in South Africa, multiple serotypes co-circulate each season with high epidemic potential, in fact the circulation of more than one highly virulent virus serotypes (e.g., BTV-1 and BTV-8) had been observed in Europe (31). Therefore, immunization of susceptible animals with a multivalent vaccine that can confer protection against multiple serotypes is ideal for the prevention of BTV outbreak. The disabled reassortant virus strains of six different serotypes that we described in this report showed great promise as suitable vaccines with all the requisite properties for animal vaccination. Indeed when these vaccine strains were mixed and the cocktail was inoculated to groups of sheep, all animals were seroconverted similar to that of single vaccine strains reported previously (12). All vaccinated animals also developed neutralizing antibodies which inhibited the replication of challenged viruses although traces of the vaccine virus RNAs were detectable following vaccination. This presence of RNA after vaccination corroborates to recently published data in sheep where vaccine RNA could be detected up to 9 dpv (32).
and up to 7 dpv in cattle (33). However none of the animals showed any clinical signs of disease after the virulent virus challenge and no trace of infectious virus replication from the challenged virus strains that could be detected by real time PCR. These results demonstrate that the multivalent cocktail vaccine afforded complete protection in sheep against each virulent serotype and there was no evidence of interference between the serotypes present in the cocktail. These results are very similar to that of previous vaccine efficacy studies in sheep with virus-like particles (VLPs) cocktails (2 or multiple serotypes), where VLPs of multiple BTV serotypes were shown to be completely protective against homologous virulent virus challenges with no interference between serotypes (34-36). These results are also consistent with the commercially available live attenuated and inactivated virus vaccines, where limited interference was observed in the cocktail BTV vaccines.

Altogether our data demonstrated that disabled BTV viruses did not replicate either in sheep or in cattle, but did confer complete protection against virulent virus challenges in both type of animals. Thus, these DISC virus vaccines are safe as subunit vaccines, but express viral proteins at the natural sites of viral infection in animal hosts similar to the natural viruses. Another advantage of this DISC virus strain is that a single strain can be used as the backbone of other serotypes by re-assortment, facilitating rapid development of highly efficacious vaccine strains. Another significant aspect of these vaccines is that these DISC strains can be used as multivalent cocktail vaccine that did not show any interference in immune response between different strains and conferred protection against all homologous virus infection.

In conclusion, our data clearly showed that the reverse genetics technology allows the generation of vaccines in a rapid and reliable manner against the threat of an outbreak of
Bluetongue regardless of the serotype involved. Emerging serotypes can therefore be rapidly prepared from genomic material to vaccine for a safe product and a robust immune response.
ACKNOWLEDGMENTS

This study was funded by the EU (FP7, ORBIVAC, number 245266) and partly by BBSRC, UK. We are thankful to P.P. C Mertens (Pirbright Institute, UK) for kindly providing the BTV challenge virus strains.
REFERENCES


Figure 1. Characterisation of reassortant disabled viruses generated by reverse genetics.

A) Left panel: Genomic profile of purified dsRNA from cells infected with the reassortant BTV-2D was analysed by non-denaturing PAGE. BTV-1 and BTV-2 profiles were included as a control. Right panel: Details of the genomic profile of dsRNA from each reassortant disabled viruses. Arrow heads indicate difference in the mobility of segments S2 or S6. 

B) Replication in normal (upper panel) or complementing cells (lower panel) of the reassortant disabled BTV strains. Monolayers of normal BSR or complementing BSR9 cell lines were infected at a multiplicity of infection (MOI) of 0.1 and samples were collected as indicated. Cells and supernatant were harvested and the total titer was determined by TCID50. Total titers at the indicated time points were expressed as TCID50/ml.

Figure 2. Detection of group-specific antibody response in vaccinated cattle sera by ELISA.

A) Antibodies directed against the VP7 protein of BTV were detected using a Competition ELISA kit. The data points represent the mean antibody response of the animals in each group (vaccinated with either BTV2D, -4D, -8D strains and control) with the standard deviation. Results were expressed as percentage of negativity (% Negativity) compared to the negative control included in the kit and were classified into positive (≤65), uncertain (>65 but ≤75) and negative (>75). Grey arrows indicate first and second vaccination time (V1 and V2) and black arrow, challenge time with homologous virulent virus serotypes (C). 

B) Early detection of IgG and IgM antibodies after first vaccination. The data represent the mean antibody response of the animals in each group with the standard deviation. The samples
were evaluated by S/P ratio (sample to positive ratio) expressed as percentage (% S/P) and were classified into positive (% S/P >30), uncertain (% S/P ≤30 but >25) and negative (% S/P ≤25).

Figure 3. Virus replication in vaccinated cattle challenged with a virulent strain.
Detection of genomic BTV RNA using a real-time RT-PCR assay in post-challenged samples from cattle vaccinated with the monoserotype vaccines. The data points represent the mean and standard deviation of RNA copy numbers of the animals in each group.

Figure 4. Detection of group-specific antibody response in sheep sera vaccinated with multivalent vaccines by ELISA.
A) Antibodies directed against the VP7 protein of BTV were detected using a Competition ELISA kit. The data points represent the mean antibody response of the animals in each group (vaccinated with the vaccine cocktail and control) with the standard deviation. Results were expressed as percentage of negativity (% Negativity) compared to the negative control included in the kit and were classified into positive (≤65), uncertain (>65 but ≤75) and negative (>75). Arrows indicate first and second vaccination time (V1 and V2) and black arrow, challenge time with homologous virulent virus serotypes (C).

B) Early detection of IgG and IgM antibodies after first vaccination. The data represent the mean antibody response of the animals in each group (vaccinated with the vaccine cocktail and control) with the standard deviation. The samples were evaluated by S/P ratio (sample to positive ratio) expressed as percentage (% S/P) and were classified into positive (% S/P >30), uncertain (% S/P ≤30 but >25) and negative (% S/P ≤25).
Figure 5. Neutralising antibody response of vaccinated sheep. Samples of sera from 576 vaccinated (grey columns) and control (open columns) animals were taken 21 days after 577 second vaccination and tested for neutralising activity against all BTV serotypes included in 578 the vaccine (BTV-1, -2, -4, -8, 13 and -21) as is indicated. Neutralising titers in each animal 579 was determined as the maximum dilution of serum that showed complete protection.

Figure 6. Clinical signs and viremia in sheep vaccinated with the multivalent cocktail 582 vaccine. A) Body temperature as sign of BT disease was recorded at different time point for 583 all animals in each group. B) Presence of genomic RNA in blood from all animals was 584 determined by real time RT-PCR at the indicated times during the experiment. V1, V2 and C 585 represent the time of first and second vaccination and challenge, respectively.